# Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer

> **NCT00398086** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 67 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT00398086
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-01
- **Primary completion:** 2008-09-01
- **Final completion:** 2010-12-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398086, "Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00398086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*